Emergent BioSolutions Inc (EBS.N)
* Emergent Biosolutions to implement stock repurchase program for up to $50 million of its common stock
BRIEF-FDA Accepts Emergent BioSolutions' supplemental biologics license application for large-scale manufacturing of BioThrax in Building 55
* FDA has set a prescription drug user fee act (PDUFA) target action date of august 15, 2016
* Emergent BioSolutions Inc receives FDA orphan drug status for BioThrax for post-exposure prophylaxis of anthrax disease
* Emergent biosolutions reports first quarter 2016 financial results
* Submits Sbla For Fda Approval Of Large Scale manufacturing of biothrax in building 55
|Merck & Co., Inc. (MRK.N)||$58.31||-0.25|
|GlaxoSmithKline plc (GSK.L)||1,667.00p||+10.00|
|Sanofi SA (SASY.PA)||€76.57||+0.06|
|Novartis AG (NOVN.S)||CHF82.50||+0.30|
|Human Genome Sciences (HGSI.OQ)||--||--|
|Bavarian Nordic A/S (BAVA.CO)||kr.245.50||+0.50|
|PharmAthene, Inc. (PIP.A)||$2.54||+0.01|
|Pfizer Inc. (PFE.N)||$36.79||+0.01|
|Johnson & Johnson (JNJ.N)||$125.05||+0.16|
|Roche Holding Ltd. (ROG.S)||CHF250.30||+1.50|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (EBS). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Emergent BioSolutions Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.